Safety of off-label erythropoiesis-stimulating agents for critically ill patients

Bita Mesgarpour, Benedikt H. Heidinger, Dominik Roth, Susanne Schmitz, Cathal D. Walsh, Harald Herkner

Research output: Contribution to journalArticlepeer-review

Abstract

This is the protocol for a review and there is no abstract. The objectives are as follows: With a focus on safety, we aim to assess the effects of ESAs (ESAs alone or in combination) compared with placebo, no treatment or a different active treatment regimen when administered off-label to critically ill patients. We will further describe and explore heterogeneity and will assess the influence of bias on the robustness of our effect estimates.

Original languageEnglish
Article numberCD010969
JournalCochrane Database of Systematic Reviews
Volume2014
Issue number2
DOIs
Publication statusPublished - 12 Feb 2014
Externally publishedYes

Fingerprint

Dive into the research topics of 'Safety of off-label erythropoiesis-stimulating agents for critically ill patients'. Together they form a unique fingerprint.

Cite this